# FCGR2B

Source: https://onco.cc/targets/fcgr2b/  
OnCo record `fcgr2b` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

FCGR2B (Low affinity immunoglobulin gamma Fc region receptor II-b) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer and Non-Hodgkin lymphoma.

## Summary

Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells.

CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.66 (direct and indirect evidence; datatypes literature 0.95, animal model 0.42, genetic association 0.36, somatic mutation 0.95). IntOGen calls it a driver in 1 cohort (0 activating, 1 loss-of-function), covering Malignant Lymphoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: Fc gamma receptor IIb; Low affinity immunoglobulin gamma Fc region receptor II-b; CD32; CD32B; FcgammaRIIb; FcGRIIB; FCG2; FCGR2
- Tags: cancer-genes-wave
- Symbol: FCGR2B
- Class: tumor-suppressor
- Biology: Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis. Location: Cell membrane (UniProt). Locus 1q23.3 (HGNC).
- Where found: Breast cancer: Open Targets association 0.50 with breast cancer (MONDO_0007254); CIViC evidence names this disease; Non-Hodgkin lymphoma: IntOGen driver in 1 cohort (MLYM)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:3618: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3618
- UniProt P31994: https://www.uniprot.org/uniprotkb/P31994/entry
- NCBI Gene 2213: https://www.ncbi.nlm.nih.gov/gene/2213
- Ensembl ENSG00000072694: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000072694

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)

---
JSON: https://onco.cc/api/v1/entities/fcgr2b.json